Results 281 to 290 of about 73,761 (306)
Some of the next articles are maybe not open access.
Annals of Pharmacotherapy, 2006
Objective: To review the pharmacokinetics, efficacy, adverse effects, and clinical trials of modified-release tacrolimus (MR-4) concerning its equivalence to non-modified-release tacrolimus. Data Sources: A PubMed/MEDLINE search was conducted (1966–July 2005) using the following terms: MR-4, tacrolimus, FK506, Prograf, transplantation, calcineurin ...
Marie A. Chisholm, Matthew D Middleton
openaire +3 more sources
Objective: To review the pharmacokinetics, efficacy, adverse effects, and clinical trials of modified-release tacrolimus (MR-4) concerning its equivalence to non-modified-release tacrolimus. Data Sources: A PubMed/MEDLINE search was conducted (1966–July 2005) using the following terms: MR-4, tacrolimus, FK506, Prograf, transplantation, calcineurin ...
Marie A. Chisholm, Matthew D Middleton
openaire +3 more sources
Journal of the American Academy of Dermatology, 2004
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial.
Irina V. Haller +2 more
openaire +3 more sources
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial.
Irina V. Haller +2 more
openaire +3 more sources
Tacrolimus in transplant rejection
Expert Opinion on Pharmacotherapy, 2012Renal transplantation is the best therapy for patients with end-stage renal disease. To avoid graft rejection, adequate immunosuppressive therapy is crucial. Tacrolimus is approved for prophylaxis of transplant rejection in liver, kidney or heart allograft recipients and for the treatment of allograft rejection resistant to treatment with other ...
openaire +3 more sources
CYCLOSPORINE AND TACROLIMUS IN DERMATOLOGY
Dermatologic Clinics, 2001Immune modulators are being used with increasing frequency in dermatology. This article reviews two such agents, cyclosporine and tacrolimus. Discussion emphasizes the pharmacology, side effects, and uses of these two drugs in dermatologic disorders.
Jennifer Clay Cather +2 more
openaire +2 more sources
Tacrolimus as an Immunomodulator
2004The immunopharmacological modulation of the immune response plays a key role in transplantation medicine. During the first 30 years of organ transplantation glucocorticosteroids and cytotoxic substances, such as azathioprine and cyclophosphamide, were the drugs most frequently used to prevent graft rejection. The introduction of cyclosporin in the year
T. Assmann, T. Ruzicka, B. Homey
openaire +2 more sources
Ranolazine-Tacrolimus Interaction
Annals of Pharmacotherapy, 2010Objective: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus concentrations within 24 hours of initiating ranolazine. Case Summary: A 64-year-old kidney allograft recipient on a stable dose of tacrolimus (10 mg twice daily) was admitted for recent worsening of her chronic anginal ...
Dwayne A. Pierce, Amber Reeves-Daniel
openaire +2 more sources
Clinical Pharmacokinetics of Tacrolimus
Clinical Pharmacokinetics, 1995Tacrolimus, a novel macrocyclic lactone with potent immunosuppressive properties, is currently available as an intravenous formulation and as a capsule for oral use, although other formulations are under investigation. Tacrolimus concentrations in biological fluids have been measured using a number of methods, which are reviewed and compared in the ...
Arun Swaminathan +9 more
openaire +3 more sources
Journal of Neuro-Ophthalmology, 2018
Background: Tacrolimus (FK506, Prograf) is a potent immunosuppressant, which inhibits cytokine synthesis and blocks T-cell development. Optic neuropathy from tacrolimus toxicity is very uncommon but, when present, can result in severe vision loss.
Sashank Prasad +4 more
openaire +3 more sources
Background: Tacrolimus (FK506, Prograf) is a potent immunosuppressant, which inhibits cytokine synthesis and blocks T-cell development. Optic neuropathy from tacrolimus toxicity is very uncommon but, when present, can result in severe vision loss.
Sashank Prasad +4 more
openaire +3 more sources
Tacrolimus in heart transplantation
Transplantation Proceedings, 2003Tacrolimus (Tac), which blocks T- and B-cell proliferation by inhibiting calcineurin, was first used for immunosuppression following heart transplant (HT) in 1989. Two multicenter randomized trials have compared Tac to the oil-based cyclosporine (CsA) formulation (both combined with azathioprine and steroids) in HT patients.
openaire +3 more sources
Tacrolimus in rheumatoid arthritis
Expert Opinion on Pharmacotherapy, 2005Tacrolimus is an immunosuppressive drug that has been used widely in organ transplantation and topically for atopic dermatitis. Tacrolimus exerts its immunosuppressive effects by the inhibition of calcineurin, leading to interference with T-cell activation.
Richard L Stern +2 more
openaire +3 more sources